Curium, led by CEO Renaud Dehareng, is advancing radioligand therapy to transform oncology by addressing up to 80% of cancers. The global radiopharmaceutical market is projected to exceed $35bn by 2035, highlighting the scale of this endeavor. Curium is investing heavily in research and development, focusing on prostate tumors, to expand its pipeline and meet future demands. The company’s commitment to robust supply chains seeks to make theranostics a routine part of cancer care, impacting millions worldwide.
